[go: up one dir, main page]

GT200600218A - FORMULATION AND PROCESS OF DIRECT COMPRESSION - Google Patents

FORMULATION AND PROCESS OF DIRECT COMPRESSION

Info

Publication number
GT200600218A
GT200600218A GT200600218A GT200600218A GT200600218A GT 200600218 A GT200600218 A GT 200600218A GT 200600218 A GT200600218 A GT 200600218A GT 200600218 A GT200600218 A GT 200600218A GT 200600218 A GT200600218 A GT 200600218A
Authority
GT
Guatemala
Prior art keywords
dpp
drug
compressed
excipients
tablets
Prior art date
Application number
GT200600218A
Other languages
Spanish (es)
Inventor
James Kowalski
Jay Parthiban Lakshman
Arun P Patel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37198127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600218(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200600218A publication Critical patent/GT200600218A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INHIBIDOR DE DIPEPTIDASA IV DE PUREZA ENTRE 98.5-100% ES UN FÁRMACO DE ALTA DOSIS QUE PUEDE SER COMPRIMIDO DIRECTAMENTE CON GLITAZONA Y EXCIPIENTES ESPECÍFICOS PARA COMERCIALIZACIÓN EN FORMAS DOSIFICADAS COMO TABLETAS Y CÁPSULAS TENIENDO LA DUREZA DESEADA, CAPACIDADES DE DESINTEGRACIÓN Y DISOLUCIÓN ACEPTABLES. DPP-IV NO ES COMPRIMIBLE DE FORMA INHERENTE Y POR ESTO PRESENTÓ PROBLEMAS DE FORMULACIÓN CON ANTERIORIDAD. LOS EXCIPIENTES UTILIZADOS MEJORAN LAS PROPIEDADES DE FLUJO Y COMPACTACIÓN DEL FÁRMACO Y LA MEZCLA DE TABLETEO. UN FLUJO ÓPTIMO CONTRIBUYE A UN LLENADO Y CONTROL DE PESO UNIFORME. EL AGREGANTE USADO ASEGURA SUFICIENTE COHESIVIDAD QUE PERMITA QUE EL DPP-IV SEA COMPRIMIDO USANDO EL MÉTODO DIRECTO. LAS TABLETAS PRODUCIDAS PROVEEN UN PERFIL DE DISOLUCIÓN IN VITRO ACEPTABLE.DIPEPTIDASA IV PURITY INHIBITOR BETWEEN 98.5-100% IS A HIGH DOSE DRUG THAT CAN BE DIRECTLY COMPRESSED WITH GLITAZONE AND SPECIFIC EXCIPIENTS FOR COMMERCIALIZATION IN DOSED FORMS AS TABLETS AND CAPSULES DISPOSED DISPOSITIONING AND DISCLAIMING CAPACITY. DPP-IV IS NOT COMPRESSIBLE INHERENTLY AND THEREFORE PRESENTED FORMULATION PROBLEMS ABOVE. THE EXCIPIENTS USED IMPROVE THE FLOW AND COMPACT PROPERTIES OF THE DRUG AND THE TABLET MIXTURE. AN OPTIMAL FLOW CONTRIBUTES TO A FILLING AND UNIFORM WEIGHT CONTROL. THE USED AGGREGANT ENSURES SUFFICIENT COHESIVITY THAT ALLOWS THE DPP-IV TO BE COMPRESSED USING THE DIRECT METHOD. PRODUCED TABLETS PROVIDE AN ACCEPTABLE IN VITRO DISSOLUTION PROFILE.

GT200600218A 2005-06-10 2006-05-24 FORMULATION AND PROCESS OF DIRECT COMPRESSION GT200600218A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68973905P 2005-06-10 2005-06-10
US69052705P 2005-06-14 2005-06-14
US69081405P 2005-06-15 2005-06-15

Publications (1)

Publication Number Publication Date
GT200600218A true GT200600218A (en) 2007-03-28

Family

ID=37198127

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600218A GT200600218A (en) 2005-06-10 2006-05-24 FORMULATION AND PROCESS OF DIRECT COMPRESSION

Country Status (14)

Country Link
US (1) US20080193529A1 (en)
EP (1) EP1893236A2 (en)
JP (1) JP2008543767A (en)
KR (1) KR20080018257A (en)
AR (1) AR054382A1 (en)
AU (2) AU2006258013A1 (en)
BR (1) BRPI0613567A2 (en)
CA (1) CA2610412A1 (en)
GT (1) GT200600218A (en)
MX (1) MX2007015612A (en)
PE (1) PE20070165A1 (en)
SA (1) SA06270158B1 (en)
TW (1) TW200716175A (en)
WO (1) WO2006135693A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
DE102005035891A1 (en) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
JOP20180109A1 (en) * 2005-09-29 2019-01-30 Novartis Ag New Formulation
KR101452915B1 (en) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 Polymorphism
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
EA015180B1 (en) 2007-02-01 2011-06-30 Такеда Фармасьютикал Компани Лимитед Solid preparation comprising alogliptin and pioglitazone
CL2008002427A1 (en) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Pharmaceutical composition comprising 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) benzyl] -benzene combined with 1 - [(4-methylquinazolin- 2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -aminopiperidin-1-yl) xanthine; and its use to treat type 2 diabetes mellitus.
UY31291A1 (en) * 2007-08-16 2009-03-31 PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-0-GLUCOSIDO
PE20140960A1 (en) * 2008-04-03 2014-08-15 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
AU2014262269B2 (en) * 2008-04-03 2017-02-02 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
KR20190016601A (en) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
MX2011002558A (en) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Combination therapy for the treatment of diabetes and related conditions.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101054911B1 (en) 2008-10-17 2011-08-05 동아제약주식회사 Pharmaceutical composition for the prevention and treatment of diabetes or obesity containing a compound that inhibits the activity of dipeptidyl peptidase-IV and other anti-diabetic or anti-obesity drugs as an active ingredient
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
PT2395983T (en) 2009-02-13 2020-07-03 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
UY32427A (en) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, METHODS OF TREATMENT AND USES OF THE SAME
SI2459531T1 (en) * 2009-07-31 2020-02-28 Krka, D.D., Novo Mesto Granulate comprising vildagliptin and process for its preparation
KR20120107080A (en) 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
MX2012012438A (en) * 2010-05-05 2012-11-29 Boehringer Ingelheim Int Pharmaceutical formulations comprising pioglitazone and linagliptin.
KR101927068B1 (en) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 Sequential Combination Therapy by the Weight Reducing Treatment Followed by the DPP-4 Inhibitor
KR20220025926A (en) 2010-06-24 2022-03-03 베링거 인겔하임 인터내셔날 게엠베하 Diabetes therapy
AR083878A1 (en) 2010-11-15 2013-03-27 Boehringer Ingelheim Int VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
UY33937A (en) 2011-03-07 2012-09-28 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS
CN103781788B (en) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 Quinazoline, its preparation and the purposes in pharmaceutical composition thereof being substituted
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6224084B2 (en) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Xanthine derivatives as DPP-4 inhibitors for the treatment of glomerular epithelial cell related disorders and / or nephrotic syndrome
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
CN102657626B (en) * 2012-05-23 2013-07-17 重庆康刻尔制药有限公司 Medicinal composite tablet of pioglitazone medicine
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014193528A1 (en) * 2013-04-29 2014-12-04 Anovel Pharmaceuticals, Llc Amorphous dosage forms and methods
JP5922310B2 (en) * 2013-07-25 2016-05-24 株式会社三和化学研究所 Pharmaceutical formulation
JP6615109B2 (en) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Medical use of DPP-4 inhibitors
MX390363B (en) 2016-06-10 2025-03-20 Boehringer Ingelheim Int Combinations of linagliptin and metformin
JP7379189B2 (en) * 2020-01-31 2023-11-14 沢井製薬株式会社 Coated particles containing vildagliptin, orally disintegrating tablets containing vildagliptin, method for producing coated particles containing vildagliptin, and method for producing orally disintegrating tablets containing vildagliptin
TR202010700A2 (en) * 2020-07-06 2022-01-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A FORMULATION CONTAINING VILDAGLIPTIN AND AT LEAST ONE PHARMACEUTICALLY ACCEPTABLE EXCLUSIVE

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
DK1741446T3 (en) * 2000-01-21 2008-06-02 Novartis Pharma Ag Combinations containing dipeptidyl peptidase IV inhibitors and antidiabetic agents
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
EP1329217A4 (en) * 2000-10-06 2007-04-04 Takeda Pharmaceutical SOLID PREPARATIONS
US6573287B2 (en) * 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
DE10308355A1 (en) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl-substituted alkanoic acid derivatives, process for their preparation and their use as medicaments
US20040186046A1 (en) * 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
ATE534404T1 (en) * 2003-10-03 2011-12-15 Takeda Pharmaceutical DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES PATIENTS WITH SECONDARY FAILURE DUE TO SULFONYL UREAS
US20090253752A1 (en) * 2004-10-25 2009-10-08 Bryan Burkey Combination of dpp-iv inhibitor, ppar antidiabetic and metmorfin

Also Published As

Publication number Publication date
PE20070165A1 (en) 2007-03-09
TW200716175A (en) 2007-05-01
EP1893236A2 (en) 2008-03-05
KR20080018257A (en) 2008-02-27
CA2610412A1 (en) 2006-12-21
WO2006135693A3 (en) 2007-02-15
AU2006258013A1 (en) 2006-12-21
US20080193529A1 (en) 2008-08-14
SA06270158B1 (en) 2010-10-23
BRPI0613567A2 (en) 2011-01-18
JP2008543767A (en) 2008-12-04
AR054382A1 (en) 2007-06-20
MX2007015612A (en) 2008-02-25
WO2006135693A2 (en) 2006-12-21
AU2010212516A1 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
GT200600218A (en) FORMULATION AND PROCESS OF DIRECT COMPRESSION
ECSP18089087A (en) FORMULATION FOR DIRECT COMPRESSION AND PROCESS
AR039335A1 (en) HIGH DRUG LOAD TABLET
AR038527A1 (en) DOSAGE FORM CONTAINING A PDE 4 INHIBITOR AS ACTIVE INGREDIENT
AR052878A1 (en) FORMULATION OF DIRECT COMPRESSION AND PROCESS
MX2011013539A (en) SOLID FARMACO TABLETS FOR IMPLANTABLE DEVICES TO MANAGE PHARMACOS.
CO7131367A2 (en) Composite formulation comprising a spherical tablet of multiple units (must) in capsule in hard capsule and method for its preparation
GT200600096A (en) PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT
ECSP088974A (en) IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHEOSE QUINASA GLYCOGEN (GSK3)
ES2687651T3 (en) Glucagon-like peptide-2 compositions and methods for producing and using them
CL2016001411A1 (en) Solid pharmaceutical dosage unit of oral disintegration comprising an estetrol component; Preparation method; use for female contraception and in female hormone replacement therapy.
AR075369A1 (en) COMPRESSED FOR COMBINATION THERAPY FOR THE TREATMENT OF VIRAL INFECTIONS.
CL2008000823A1 (en) Immediate release pharmaceutical formulation comprising dapagliflozin propylene glycol hydrate and a pharmaceutically acceptable carrier; Use to treat diabetes, glucose intolerance, insulin resistance, among others.
ES2916649T1 (en) Compositions and uses for the treatment of multiple sclerosis
CL2011000642A1 (en) Dosing unit comprising 25 to 400 mg of the acid 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic; pharmaceutical kit comprising the dosage unit; and its use for the treatment of cystic fibrosis.
AR037930A1 (en) DIRECTLY COMPRESSIBLE ACITHROMYCIN FORMULATIONS
MX2018016330A (en) COMBINATIONS FOR CANCER TREATMENT.
MX2015017697A (en) COMPOSITION OF TRADITIONAL CHINESE MEDICINE, AND PREPARATION AND APPLICATION OF THE SAME.
AR076519A1 (en) COAGLOMERATES OF COMPRESSIBLE AND FREE FLUIDITY GRANULAR MANITOL AND ALMIDON. PREPARATION PROCEDURE
AR069508A1 (en) DERIVATIVES OF QUINOLINA 057; A PROCESS FOR PREPARATION; A PHARMACEUTICAL COMPOSITION; THE PREPARATION OF THIS AND THE USE OF THE COMPOUND TO PREPARE A MEDICINAL PRODUCT
AR034638A1 (en) METHOD AND DEVICE FOR PRODUCING COMPRESSION COATED TABLETS
AR105184A1 (en) IMMEDIATE RELEASE TABLETS CONTAINING A DRUG AND PROCESSES TO FORM THE TABLETS
AR127064A1 (en) PRODRUGS OF PYRROLIDONE DERIVATIVES AS A GLUCOKINASE ACTIVATOR
AR057932A1 (en) COMPRESSED BICYPE THAT INCLUDES TELMISARTAN AND DIURETICO
UY28979A1 (en) DERIVATIVES OF 3-CARBOXAMIDE HYDROCLORURES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURE AND ITS USE, USED AS SELECTED INHIBITORS OF GSK3